

FIG. 4. Kaplan-Meier plots of overall survival according to α_1 -antitrypsin (A) and α_1 -antichymotrypsin (B) levels.

the survival outcome (Fig. 5A). The accuracy of the nomogram for prognostication was internally validated. The bootstrap-corrected concordance index was 0.672, and the calibration curve demonstrated good agreement between the predicted and observed outcomes (Fig. 5B). It was possible to estimate high risk patients by calculating the total points using the nomogram. The median survival time was 150 days (95% CI, 123–187 days) for patients with a total point score of >94 ($n = 98$) and 282 days (95% CI, 255–328 days) for patients with a score of ≤ 94 ($n = 206$), and the difference was significant ($p = 2.00 \times 10^{-15}$, log rank test; Fig. 5C). Even when the 60 patients used for 2DICAL analyses were excluded from the total points calculation, the difference was still significant ($p = 5.23 \times 10^{-10}$; supplemental Fig. S2C). The median survival time was 171 days (95% CI, 147–205 days) for patients with a score of >92 ($n = 83$) and 270 days (95% CI, 243–299 days) for patients with a score of ≤ 92 ($n = 161$). The cutoff value that optimally segregated patients into subgroups with a poor and good prognosis was determined by using the maximally selected statistics.

DISCUSSION

Currently, no diagnostic tool has been established for stratifying patients with advanced pancreatic cancer according to their likelihood of obtaining a survival benefit from gemcitabine treatment. Because some high risk patients may achieve prolonged survival through modification (or even withdrawal) of therapeutic protocols, a diagnostic method that can accurately identify such patients is necessary. We first compared the plasma proteome of two groups of patients who showed distinct clinical courses after receiving the same gemcitabine protocol (Fig. 1) and found that individuals who showed poor clinical courses had shown high base-line levels of plasma α_1 -antitrypsin and α_1 -antichymotrypsin (Figs. 1B and 2A). α_1 -Antitrypsin is an abundant plasma protein that usually cannot be measured by MS. However, antibody-based protein depletion (30) allowed us to accentuate the differences in α_1 -antitrypsin levels.

The results obtained by 2DICAL were then validated in a 5-fold larger cohort using a different methodology: high density reverse-phase protein microarray (Figs. 3 and 4 and Table II). Reverse-phase protein microarray is an emerging proteomics technology capable of validating new biomarkers because of its overwhelmingly high throughput (31, 32). Furthermore, reverse-phase protein microarrays require significantly smaller amounts of clinical samples for quantification than established clinical tests, such as ELISA. The prognostic significance of α_1 -antitrypsin was further supported by multivariate survival analysis with stepwise covariate selection. The level of α_1 -antitrypsin was selected as the second most significant factor following alkaline phosphatase (Table II), but α_1 -antichymotrypsin was not selected. To derive clinical applicability from the above findings, we constructed a model (nomogram) including α_1 -antitrypsin to estimate the survival period of pancreatic cancer patients (Fig. 5A), and its significance was internally validated (Fig. 5B). One previous study has demonstrated a correlation between an increased serum level of α_1 -antitrypsin and short survival in patients treated surgically for pancreatic cancer (33). Although the number of cases examined was small ($n = 44$), the results support our present findings.

α_1 -Antitrypsin and α_1 -antichymotrypsin are members of the serine protease inhibitor (serpin) superfamily that plays key roles in the regulation of inflammatory cascades (34, 35). α_1 -Antitrypsin and α_1 -antichymotrypsin interact mainly with neutrophil elastase and neutrophil cathepsin G, respectively, and inhibit their protease activities (36). A protease-to-protease inhibitor imbalance in patients with genetic α_1 -antitrypsin deficiency is reported to confer a higher risk of chronic pancreatitis (37). However, the serum level of α_1 -antitrypsin in patients with pancreatic cancer varied significantly from case to case, and its clinical significance has remained unclear. We showed that increased concentrations of α_1 -antitrypsin and α_1 -antichymotrypsin in plasma/serum correlated with poor




FIG. 5. A, nomogram for estimating the probability (Prob) of survival 6, 12, and 24 months (mo) after gemcitabine treatment. See supplemental Fig. S4 and its legend for details of usage. B, calibration curve demonstrating the correlation between predicted and actual survival at 12 months after gemcitabine treatment. Bars represent 95% CI. C, Kaplan-Meier plots of overall survival according to total points. ALP, alkaline phosphatase.

survival, indicating that patients with poor outcomes have lower base-line protease activities than those with favorable outcomes. How such a protease imbalance affects the progression of pancreatic cancer awaits further clarification in future studies.

In conclusion, we identified a prognostic biomarker potentially useful for selecting high risk patients with advanced pancreatic cancer who are unlikely to gain adequate survival benefit from the standard treatment. This may be of great clinical importance, especially when an alternative therapeutic option becomes available for patients with advanced pancreatic cancer in the future. However, the level of α ₁-antitrypsin was not significantly correlated with the efficacy of gemcitabine, indicating that it may reflect the natural course of pancreatic cancer irrespective of treatment.

Therefore, an independent prospective validation study will be definitely necessary to confirm the universality of the present findings. The absolute concentration of α ₁-antitrypsin can be measured by nephelometry, but this measurement requires a larger sample volume than reverse-phase microarrays and for this reason could not be performed in this study. While bearing all these limitations in mind, the present findings may not only help to stratify patients with pancreatic cancer but also provide novel insights into the molecular mechanisms behind the malignant progression of this neoplasm, possibly leading to the development of novel therapeutic strategies.

Acknowledgments—We thank Ayako Igarashi, Tomoko Umaki, and Yuka Nakamura for technical assistance.

* This work was supported by the "Program for Promotion of Fundamental Studies in Health Sciences" conducted by the National Institute of Biomedical Innovation of Japan and the "Third-Term Comprehensive Control Research for Cancer" and "Research on Biological Markers for New Drug Development" conducted by the Ministry of Health and Labor of Japan.

☐ This article contains supplemental Figs. S1–S4 and Table S1.

✉ To whom correspondence should be addressed: Chemotherapy Division, National Cancer Center Research Inst., 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Tel.: 81-3-3542-2511; Fax: 81-3-3547-6045; E-mail: jmatsuba@ncc.go.jp.

REFERENCES

- Honda, K., Hayashida, Y., Umaki, T., Okusaka, T., Kosuge, T., Kikuchi, S., Endo, M., Tsuchida, A., Aoki, T., Itoi, T., Moriyasu, F., Hirohashi, S., and Yamada, T. (2005) Possible detection of pancreatic cancer by plasma protein profiling. *Cancer Res.* **65**, 10613–10622
- American Cancer Society (2007) *Cancer Facts and Figures 2007*, pp. 16–17, American Cancer Society, Atlanta, GA
- Ministry of Health, Labour and Welfare (2009) *Japanese Government: Vital Statistics of Japan*, Ministry of Health, Labour and Welfare, Tokyo
- Rosewicz, S., and Wiedenmann, B. (1997) Pancreatic carcinoma. *Lancet* **349**, 485–489
- Nieto, J., Grossbard, M. L., and Kozuch, P. (2008) Metastatic pancreatic cancer 2008: is the glass less empty? *Oncologist* **13**, 562–576
- National Comprehensive Cancer Network (2009) *Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma*, Vol. 1, National Comprehensive Cancer Network, Fort Washington, PA
- Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J. Clin. Oncol.* **15**, 2403–2413
- Matsubara, J., Ono, M., Negishi, A., Ueno, H., Okusaka, T., Furuse, J., Furuta, K., Sugiyama, E., Saito, Y., Kaniwa, N., Sawada, J., Honda, K., Sakuma, T., Chiba, T., Saijo, N., Hirohashi, S., and Yamada, T. (2009) Identification of a predictive biomarker for hematologic toxicities of gemcitabine. *J. Clin. Oncol.* **27**, 2261–2268
- Stocken, D. D., Hassan, A. B., Altman, D. G., Billingham, L. J., Bramhall, S. R., Johnson, P. J., and Freemantle, N. (2008) Modelling prognostic factors in advanced pancreatic cancer. *Br. J. Cancer* **99**, 883–893
- Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitino, E., Taïeb, J., Faroux, R., Lepere, C., and de Gramont, A. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. *J. Clin. Oncol.* **23**, 3509–3516
- Storniolo, A. M., Enas, N. H., Brown, C. A., Voi, M., Rothenberg, M. L., and Schilsky, R. (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. *Cancer* **85**, 1261–1268
- Hanash, S. (2003) Disease proteomics. *Nature* **422**, 226–232
- Yamaguchi, U., Nakayama, R., Honda, K., Ichikawa, H., Hasegawa, T., Shitashige, M., Ono, M., Shoji, A., Sakuma, T., Kuwabara, H., Shimada, Y., Sasako, M., Shimoda, T., Kawai, A., Hirohashi, S., and Yamada, T. (2008) Distinct gene expression-defined classes of gastrointestinal stromal tumor. *J. Clin. Oncol.* **26**, 4100–4108
- Hayashida, Y., Honda, K., Osaka, Y., Hara, T., Umaki, T., Tsuchida, A., Aoki, T., Hirohashi, S., and Yamada, T. (2005) Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. *Clin. Cancer Res.* **11**, 8042–8047
- Taguchi, F., Solomon, B., Gregorc, V., Roder, H., Gray, R., Kasahara, K., Nishio, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P. P., Dziadziszko, R., Schiller, J., Grigorieva, J., Tsypin, M., Hunsucker, S. W., Caprioli, R., Duncan, M. W., Hirsch, F. R., Bunn, P. A., Jr., and Carbone, D. P. (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. *J. Natl. Cancer Inst.* **99**, 838–846
- Ono, M., Shitashige, M., Honda, K., Isobe, T., Kuwabara, H., Matsuzuki, H., Hirohashi, S., and Yamada, T. (2006) Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. *Mol. Cell. Proteomics* **5**, 1338–1347
- Negishi, A., Ono, M., Handa, Y., Kato, H., Yamashita, K., Honda, K., Shitashige, M., Satow, R., Sakuma, T., Kuwabara, H., Omura, K., Hirohashi, S., and Yamada, T. (2009) Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. *Cancer Sci.* **100**, 514–519
- Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jr., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruija, G., and Miller, L. L. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. *J. Clin. Oncol.* **22**, 3776–3783
- Van Cutsem, E., Verenne, W. L., Bannoun, J., Humblet, Y., Gill, S., Van Laethem, J. L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., and Moore, M. J. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. *J. Clin. Oncol.* **27**, 2231–2237
- Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekas, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., Vehlning-Kaiser, U., Fuchs, M., Fleckenstein, D., Gesierich, W., Uthgenannt, D., Einsele, H., Holstege, A., Hinke, A., Schalthorn, A., and Wilkowski, R. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. *J. Clin. Oncol.* **24**, 3946–3952
- Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., and Parulekar, W. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J. Clin. Oncol.* **25**, 1960–1966
- Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., Köhne, C. H., Mingrone, W., Stemmer, S. M., Tamas, K., Kornek, G. V., Koeberle, D., Cina, S., Bernhard, J., Dietrich, D., and Scheithauer, W. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *J. Clin. Oncol.* **25**, 2212–2217
- Japan Pancreas Society (ed) (2002) *General Rules for the Study of Pancreatic Cancer*, 5th Ed., Kanehara, Tokyo
- Sugiyama, E., Kaniwa, N., Kim, S. R., Kikura-Hanajiri, R., Hasegawa, R., Maekawa, K., Saito, Y., Ozawa, S., Sawada, J., Kamatani, N., Furuse, J., Ishii, H., Yoshida, T., Ueno, H., Okusaka, T., and Saijo, N. (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. *J. Clin. Oncol.* **25**, 32–42
- Honda, K., Yamada, T., Hayashida, Y., Idogawa, M., Sato, S., Hasegawa, F., Ino, Y., Ono, M., and Hirohashi, S. (2005) Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. *Gastroenterology* **128**, 51–62
- Idogawa, M., Yamada, T., Honda, K., Sato, S., Imai, K., and Hirohashi, S. (2005) Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. *Gastroenterology* **128**, 1919–1936
- Hothorn, T., and Zeileis, A. (2008) Generalized maximally selected statistics. *Biometrics* **64**, 1263–1269
- Wang, S. J., Fuller, C. D., Kim, J. S., Sittig, D. F., Thomas, C. R., Jr., and Ravdin, P. M. (2008) Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. *J. Clin. Oncol.* **26**, 2112–2117
- Storey, J. D., and Tibshirani, R. (2003) Statistical significance for genome-wide studies. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 9440–9445
- Huang, L., Harvie, G., Feitelson, J. S., Gramatikoff, K., Herold, D. A., Allen, D. L., Amunngama, R., Hagler, R. A., Pisanò, M. R., Zhang, W. W., and Fang, X. (2005) Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. *Proteomics* **5**, 3314–3328
- Grote, T., Siwak, D. R., Fritsche, H. A., Joy, C., Mills, G. B., Simeone, D.,

- Whitcomb, D. C., and Logsdon, C. D. (2008) Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. *Proteomics* **8**, 3051-3060
32. Wulfskuhle, J. D., Liotta, L. A., and Petricoin, E. F. (2003) Proteomic applications for the early detection of cancer. *Nat. Rev. Cancer* **3**, 267-275
33. Trichopoulos, D., Tzonou, A., Kalapothaki, V., Sparos, L., Kremastinou, T., and Skoutari, M. (1990) Alpha 1-antitrypsin and survival in pancreatic cancer. *Int. J. Cancer* **45**, 685-686
34. Lomas, D. A., and Mahadeva, R. (2002) Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. *J. Clin. Investig.* **110**, 1585-1590
35. Stoller, J. K., and Aboussouan, L. S. (2005) Alpha1-antitrypsin deficiency. *Lancet* **365**, 2225-2236
36. Beatty, K., Bieth, J., and Travis, J. (1980) Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. *J. Biol. Chem.* **255**, 3931-3934
37. Rabassa, A. A., Schwartz, M. R., and Ertan, A. (1995) Alpha 1-antitrypsin deficiency and chronic pancreatitis. *Dig. Dis. Sci.* **40**, 1997-2001

Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 Cases

Eiichiro Suzuki^{a,b} Junji Furuse^b Masafumi Ikeda^a Takuji Okusaka^c
Kohei Nakachi^a Shuichi Mitsunaga^a Hideki Ueno^c Chigusa Morizane^c
Shunsuke Kondo^c Satoshi Shimizu^a Yasushi Kojima^c Atsushi Hagihara^c

^aDivision of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba,

^bDepartment of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, and

^cDivision of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan

Key Words

Biliary tract cancer · Gemcitabine · Monotherapy ·
Prognostic factors · Treatment efficacy · Treatment safety

Abstract

Aim: The purpose of this study was to elucidate the treatment efficacy and safety of gemcitabine monotherapy, and to identify prognostic factors in patients with advanced biliary tract cancer receiving this therapy. **Method:** The data of 100 patients with advanced biliary tract cancer who were treated with gemcitabine as first-line chemotherapy were reviewed retrospectively. **Results:** One patient showed complete response (1.0%) and 6 patients showed partial response (6.0%), yielding an overall response rate of 7.0%. The main grade 3/4 toxicities were neutropenia and leukopenia. The median survival, 1-year survival rate and progression-free survival were 7.3 months, 21.6% and 3.1 months, respectively. Multivariate analysis identified a performance status of 0–1, serum C-reactive protein level of <3.0 mg/dl, serum carcinoembryonic antigen level of <10 ng/ml and serum albumin level of ≥3.5 g/dl as factors independently associated with a favorable prognosis. **Conclusions:** Gemcitabine

monotherapy showed modest efficacy with manageable toxicity in patients with biliary tract cancer. These results could be useful as reference data for optimizing treatment strategies and planning future clinical trials in patients with advanced biliary tract cancer. Copyright © 2010 S. Karger AG, Basel

Introduction

Biliary tract cancer (BTC) is uncommon in western countries, but it is a common cancer-related death in Japan, with an estimated 16,000 deaths occurring annually [1]. Surgery currently remains the only potentially curative treatment, but the majority of patients are diagnosed at an advanced stage of the disease because of the lack of early symptoms. Moreover, even in patients treated with surgical resection, the risk of recurrence is extremely high [2]. Although systemic chemotherapy is indicated

This study was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health and Welfare, Japan.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2010 S. Karger AG, Basel
0030-2414/10/0792-0039\$26.00/0

Accessible online at:
www.karger.com/ocf

Eiichiro Suzuki, MD
Department of Internal Medicine, Medical Oncology
Kyorin University School of Medicine
6-20-2 Shinkawa, Mitaka, Tokyo 181-8611 (Japan)
Tel. +81 422 47 5511, Fax +81 422 44 0604, E-Mail eisuzuki@ks.kyorin-u.ac.jp

for patients with unresectable disease, standard chemotherapeutic regimens have not been established in the last decades [2]. To improve survival, various agents were evaluated in clinical trials. Among these agents, gemcitabine was found to yield relatively favorable results [3, 4], and it has been administered worldwide either as a single agent or in combination with other agents for the treatment of BTC [2–5]. More recently, in a randomized phase III study of combined chemotherapy with gemcitabine and cisplatin versus gemcitabine monotherapy (UK ABC-02 study), median survival times were 11.7 and 8.3 months, respectively ($p = 0.002$) [6]. Therefore, the gemcitabine-cisplatin combination will become standard chemotherapeutic treatment for advanced BTC.

Numerous clinical trials investigating gemcitabine-based regimens have been conducted to date, but the numbers of patients have been small and only selected patients have been treated with gemcitabine. In addition, prognostic factors in BTC patients treated with gemcitabine have not yet been fully clarified. The objectives of this current study were to retrospectively review the treatment efficacy and safety of gemcitabine monotherapy, as well as to identify prognostic factors in patients with advanced BTC receiving this therapy.

Patients and Methods

Patients

One hundred sixteen patients with advanced or recurrent BTC received gemcitabine monotherapy from December 2001 to August 2007 at the National Cancer Center Hospital and National Cancer Center Hospital East. The diagnosis of BTC was confirmed histologically and/or cytologically as adenocarcinoma. Among these patients, the data of 16 patients were excluded from this analysis (a history of prior treatment in 10 patients; voluntary move to another hospital before the first tumor assessment in 3 patients and no evaluable tumor in 3 patients). A total of 100 patients had measurable lesion(s) and data were thus analyzed to elucidate the treatment efficacy and safety of gemcitabine monotherapy. The following criteria had to be met to be eligible for systemic chemotherapy, including gemcitabine monotherapy, at our institutions: Eastern Cooperative Oncology Group performance status (PS) of 0–2, adequate bone marrow function (white blood cell (WBC) count $\geq 3,000/\text{mm}^2$, absolute neutrophil count $\geq 1,000/\text{mm}^3$ and platelet count $\geq 70,000/\text{mm}^3$) and availability of written informed consent from each patient. Patients were excluded if they had severe complications. Gemcitabine was administered at a dose of $1,000 \text{ mg/m}^2$ by intravenous injection for 30 min on days 1, 8 and 15 of each 28-day cycle until disease progression, appearance of unacceptable toxicity or patient's refusal for treatment continuation. All patients underwent physical examination and assessment of toxicity at least once every 1 or 2 weeks until the completion of gemcitabine treatment. All patients with obstructive jaundice underwent percutaneous transhepatic or endoscopic retrograde bili-

ary drainage before treatment. These patients were required to have serum bilirubin levels of $<3.0 \text{ mg/dl}$ and serum AST and ALT levels <5 times the upper limit of normal.

Response and Toxicity Evaluation

The antitumor effect of gemcitabine was evaluated by CT/MRI conducted every 4–8 weeks after the start of treatment. Tumor response was determined according to the Response Evaluation Criteria in Solid Tumors [7]. The size of measurable lesions was determined using enhanced CT or MRI. For this analysis, tumor response was reviewed, and the best overall response was recorded for each patient. Toxicities were graded according to the Common Terminology Criteria for Adverse Events, version 3.0.

Analysis of Prognostic Factors

Eighteen variables were selected in this study based on previous investigations [8–11] and our own clinical experience. All data were obtained just before the start of the systemic chemotherapy. The variables, which were divided into two clinically meaningful subgroups, were as follows: age ($<65/\geq 65$ years), sex (male/female), PS (0–1 or 2), WBC count ($<8,500/\geq 8,500/\mu\text{l}$), hemoglobin level ($<12.0/\geq 12.0 \text{ g/dl}$), platelet count ($<220,000/\geq 220,000/\mu\text{l}$), serum albumin level ($<3.5/\geq 3.5 \text{ g/dl}$), serum total bilirubin level ($<2.0/\geq 2.0 \text{ mg/dl}$), serum lactate dehydrogenase (LDH) level ($<230/\geq 230 \text{ IU/l}$), serum C-reactive protein (CRP) level ($<3.0/\geq 3.0 \text{ mg/dl}$), biliary drainage (presence/absence) and prior surgical resection (presence/absence) as the host-related variables, primary tumor location (intrahepatic, extrahepatic, bile duct and ampulla of Vater/gallbladder), extent of disease (localized/metastatic), peritoneal dissemination (presence/absence), liver metastasis (presence/absence), serum carcinoembryonic antigen (CEA) level ($<10/\geq 10 \text{ ng/ml}$) and serum carbohydrate antigen 19-9 (CA 19-9) level ($<1,000/\geq 1,000 \text{ U/ml}$) as the tumor-related variables. Peritoneal dissemination was defined as recognition of peritoneal nodules on CT/MRI or positive cytology of group V ascites.

Statistical Analysis

Progression-free survival was calculated as the time interval from the 1st day of treatment to the date of detection of disease progression, last day of follow-up, or the date of death. Overall survival was calculated as the time interval from the 1st day of treatment to the date of death or the last day of follow-up. In univariate analysis, cumulative survival proportions were calculated by the Kaplan-Meier method and differences were evaluated by the log-rank test. Only variables that were identified as showing statistical significance in univariate analysis were included into Cox's proportional hazard regression model for multivariate analysis. $p < 0.05$ was considered to be statistically significant and all the tests were two-sided. All statistical analyses were performed using the SPSS statistical software package (SPSS version 11.0 for Windows).

Results

Patient Characteristics

The characteristics of the patients are shown in table 1. PS was 0 in 66 patients (66.0%), 1 in 27 patients (27.0%)

Table 1. Patient characteristics

Characteristics	Patients
Age, years, median [range]	67.5 [44–82]
Sex, n (%)	
Male	60 (60.0)
Female	40 (40.0)
PS, n (%)	
0	66 (66.0)
1	27 (27.0)
2	7 (7.0)
WBC, n/ μ l, median [range]	6,400 [3,200–17,200]
Hemoglobin, g/dl, median [range]	12.2 [6.2–15.3]
Platelets, n \times 10 ⁴ / μ l, median [range]	23.2 [7.9–56.8]
Albumin, g/dl, median [range]	3.6 [1.9–4.6]
Total bilirubin, mg/dl, median [range]	0.8 [0.2–4.1]
Lactic dehydrogenase, IU/l median [range]	203.0 [70.0–733.0]
CRP, mg/dl, median [range]	0.9 [0.0–26.3]
Primary tumor site, n (%)	
Intrahepatic bile duct	23 (23.0)
Extrahepatic bile duct	25 (25.0)
Gallbladder	45 (45.0)
Ampulla of Vater	7 (7.0)
Extent of disease, n (%)	
Locally advanced	20 (20.0)
Metastatic	80 (80.0)
Metastatic site, n (%)	
Liver	36 (36.0)
Lymph node	28 (28.0)
Peritoneal dissemination	25 (25.0)
Lung	16 (16.0)
Biliary drainage (+)	30 (30.0)
Prior surgical resection (+)	28 (28.0)
CEA, ng/ml, median [range]	6.5 [0.5–3,110.0]
CA 19-9, U/ml, median [range]	258.1 [0.0–827,000]

and 2 in 7 patients (7.0%). Twenty-three (23.0%) patients had intrahepatic bile duct cancer, 25 (25.0%) had extrahepatic bile duct cancer, 45 (45.0%) had gallbladder cancer, and 7 (7.0%) had cancer in the ampulla of Vater. The median number of cycles of gemcitabine monotherapy administered was 2.9 (range: 1–34). Eighteen patients (18.0%) received second-line treatment as follows: S-1 monotherapy, 7 patients; uracil/tegafur, 3 patients; uracil/tegafur + doxorubicin, 2 patients; immunotherapy, 3 patients, and other treatments, 3 patients.

Tumor Response

All the 100 patients had measurable primary or metastatic lesion(s). Of the 100 patients, complete response (CR) was achieved in 1 patient, partial response (PR) in 6 patients, stable disease (SD) was noted in 56 patients, and




Fig. 1. Overall survival (solid line) and progression-free survival (broken line) in patients with BTC treated with gemcitabine monotherapy.

progressive disease (PD) in 35 patients. The remaining 2 patients could not be assessed radiologically, but both were judged as showing clinical evidence of tumor progression. The overall response rate (RR) was 7.0% [95% confidence interval (CI), 2.9–13.9]. The data were also analyzed according to the tumor type. The overall RR in patients with cancer of the intrahepatic bile duct, extrahepatic biliary duct, gallbladder and ampulla of Vater were 4.2% (1/23), 8.0% (2/25), 8.8% (4/45) and 0.0% (0/7), respectively. The overall disease control rates (CR + PR + SD) in patients with cancer of the intrahepatic bile duct, extrahepatic bile duct, gallbladder and ampulla of Vater were 69.5% (16/23), 60.0% (15/25), 57.8% (26/45) and 85.7% (6/7), respectively.

Survival

By the time of the analysis, 91 of the 100 patients had died as a result of PD. The median follow-up of censored 9 patients was 7.0 months (range, 0.4–30.9).

The overall and progression-free survival curves are shown in figure 1. The median survival, 1-year survival rate and median progression-free survival were 7.3 months (95% CI, 5.4–9.2 months), 21.6% and 3.1 months (95% CI, 2.6–3.6 months), respectively. The median progression-free survival times in PR, SD and PD patients was 12.0 (95% CI 9.5–14.5), 4.3 (95% CI 2.6–6.0) and 0.8 (95% CI 0.6–1.0) months, respectively, and the overall

Table 2. Treatment-related adverse events (worst grade reported during the treatment period)

Adverse events	Toxicity grade				
	1	2	3	4	3/4 (%)
Hematological toxicity					
Leukopenia	24	18	9	0	9 (9.0)
Neutropenia	6	9	11	5	16 (16.0)
Thrombocytopenia	9	9	2	0	2 (2.0)
Anemia	18	20	3	0	3 (3.0)
Non-hematological toxicity					
Nausea/vomiting	13	0	1	0	1 (1.0)
Anorexia	22	2	2	0	2 (2.0)
Fatigue	25	2	0	0	0
Diarrhea	3	0	0	0	0
Rash	8	1	0	0	0
Decreased serum					
albumin level	13	6	2	0	2 (2.0)
Elevated serum AST	16	7	2	0	2 (2.0)
Elevated serum ALT	10	5	2	0	2 (2.0)
Elevated serum ALP	3	1	5	0	5 (5.0)
Hyponatremia	9	0	0	0	0
Cognitive disturbance	0	0	1	0	1 (1.0)
Biliary tract infection	1	0	2	0	2 (2.0)

AST = Aspartate aminotransferase; ALT = alanine aminotransferase; ALP = alkaline phosphatase.

survival times were 17.1 (95% CI 14.6–19.7), 9.7 (95% CI 8.4–10.9) and 3.2 (95% CI 2.6–3.9) months, respectively.

Toxicity

The most severe hematological and non-hematological toxicities during the entire treatment period are summarized in table 2. With regard to grade 3/4 hematological toxicities, neutropenia was observed in 16 patients (16.0%), leukopenia in 9 patients (9.0%), anemia in 3 patients (3.0%) and thrombocytopenia in 2 patients (2.0%). In regard to the main grade 3/4 non-hematological toxicities, an elevated alkaline phosphatase level was observed in 5 patients (5.0%), and other adverse events occurred in <3%. Cognitive disturbance was observed in 1 patient (1.0%); however, recovery occurred in the absence of any treatment. There were no other life-threatening toxicities and no treatment-related deaths.

Univariate Analysis

Of the 18 pretreatment variables, 12 variables (female, PS 0–1, WBC count <8,500/ μ l, hemoglobin >12.0 g/dl, serum albumin \geq 3.5 g/dl, serum total bilirubin <2.0 mg/

dl, serum LDH <230 IU/l and serum CRP <3.0 mg/dl, intrahepatic, extrahepatic, bile duct and ampulla of Vater cancer, absence of peritoneal dissemination, absence of liver metastasis and serum CEA <10 ng/ml) were identified as being significantly associated with a longer survival time (table 3).

Multivariable Analysis

The 12 variables identified by univariate analysis as being of prognostic significance were subsequently incorporated in Cox's proportional hazard model for multivariate analysis, and a PS of 0–1, serum CEA <10 ng/ml, serum albumin \geq 3.5 g/dl, and serum CRP <3.0 mg/dl were identified as being independently associated with a favorable prognosis (table 4).

Discussion

Gemcitabine has been used as a key drug for advanced BTC, and at present gemcitabine-based regimens are widely used as first-line treatment for advanced BTC. However, to date, reliable data of gemcitabine monotherapy based on large-scale studies are still lacking. This study shows not only efficacy and safety but also prognostic factors in a large study cohort.

Studies on gemcitabine monotherapy at doses of 800–2,200 mg/m² as first-line therapy for advanced BTC have reported response rates of 0–36.0%, and median survival times from 4.6 to 14.0 months [12–20]. Our overall response rate of 7.0% in BTC patients administered gemcitabine monotherapy as first-line therapy in our study was comparable to those reported from previous trials of gemcitabine monotherapy. The median survival of 7.3 months and the incidence of adverse events were also in accord with previous reports [12–20]. These findings clearly demonstrate that gemcitabine monotherapy is well tolerated in patients with advanced BTC in the clinical setting.

The study was also designed to determine prognostic factors in patients with advanced BTC administered gemcitabine monotherapy. The identification of prognostic factors can help to predict life expectancy and to select the appropriate treatment. In the current study, among the variables investigated, PS, serum CRP, serum albumin and serum CEA were found to be independently associated with patient prognosis.

PS was the strongest prognostic factor, although most of our patients (93%) had a good PS (0–1) and only 7 patients were PS 2. PS is a simple, but widely used index re-

Table 3. Univariate analysis to identify prognostic factors associated with survival in BTC patients

Variable	Patients	Median survival months	Hazard ratio (95% CI)	p value
Age				
≥65 years	59	8.4	1	0.25
<65 years	41	6.4	1.28 (0.84–1.96)	
Sex				
Female	60	9.0	1	0.02
Male	40	5.5	1.68 (1.08–2.54)	
PS				
0–1	93	8.1	1	<0.01
2	7	1.3	11.15 (4.38–28.38)	
WBC count				
≥8,500/ μ l	81	8.8	1	0.02
<8,500/ μ l	19	3.3	1.90 (1.10–3.29)	
Hemoglobin				
<12 g/dl	51	10.2	1	<0.01
≥12 g/dl	49	5.5	1.85 (1.22–2.86)	
Platelets				
≥220,000/ μ l	39	9.1	1	0.18
<220,000/ μ l	61	6.5	1.34 (0.87–2.01)	
Albumin				
≥3.5 g/dl	59	9.2	1	<0.01
<3.5 g/dl	41	5.1	2.61 (1.67–4.01)	
Total bilirubin				
<2 mg/dl	83	8.9	1	0.01
≥2 mg/dl	17	5.5	2.28 (1.19–4.37)	
LDH				
<230 IU/l	61	9.7	1	<0.01
≥230 IU/l	39	3.5	2.55 (1.64–3.94)	
CRP				
<3 mg/dl	75	9.2	1	<0.01
≥3 mg/dl	25	3.3	4.01 (2.41–6.67)	
Biliary drainage				
Absent	70	8.4	1	0.91
Present	30	6.5	1.03 (0.66–1.60)	
Prior surgical resection				
Yes	29	10.2	1	0.10
No	71	6.4	1.45 (0.93–2.27)	
Primary tumor site				
Bile duct	55	9.1	1	0.04
Gallbladder	45	6.4	1.55 (1.02–2.35)	
Extent of disease				
Localized	16	11.7	1	0.14
Metastatic	84	6.5	1.44 (0.89–2.33)	
Peritoneal dissemination				
Absent	75	8.1	1	0.04
Present	25	4.9	1.64 (1.02–2.65)	
Liver metastasis				
Absent	64	9.0	1	<0.01
Present	36	5.8	1.81 (1.17–2.79)	
CEA				
<10 ng/ml	57	9.7	1	0.01
≥10 ng/ml	43	5.8	1.73 (1.12–2.66)	
CA 19-9				
<1,000 U/ml	66	8.4	1	0.12
≥1,000 U/ml	34	5.2	1.41 (0.91–2.17)	

Bile duct = Intra- and extrahepatic bile duct/ampulla of Vater.

Table 4. Significant prognostic factors in BTC patients treated with gemcitabine determined by multivariate analysis using Cox's proportional hazard model

Variable	Hazard ratio	95% CI	p value
PS			
0–1	1		<0.01
2	5.417	2.05–14.28	
CRP			
<3 mg/dl	1		<0.01
≥3 mg/dl	2.791	1.53–5.09	
CEA			
<10 U/ml	1		<0.01
≥10 U/ml	2.138	1.36–3.36	
Albumin			
≥3.5 g/dl	1		<0.01
<3.5 g/dl	2.005	1.218–3.30	

flecting the physical condition of the patient, which has been recognized as an important prognostic factor in patients with a variety of malignancies, including BTC [10, 11]. In this study, the median survival of PS 2 patients was only 1.6 months. Thus, patients of PS 2 should not receive gemcitabine monotherapy. Serum albumin and CRP were also found to be significant prognostic factors in this study. They are interrelated, because albumin is related to systemic inflammation, which is measured by serum CRP and other cytokines [21–24]. CRP is produced by the liver and its production is induced by pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor- α , which are involved in the pathogenesis of cachexia [25, 26]. These cytokines are associated with hypermetabolism, weight loss and anorexia and, as a result, may reflect shortened survival. Serum CEA is currently the most widely used tumor marker for other malignancies [27–30]. High serum CEA has also been shown to be a poor prognostic factor in patients with other malignancies, and in agreement with these data, our results also suggest that high serum CEA levels may reflect a high tumor burden and be related to survival in BTC patients. Contrary to our expectation, the primary site of cancer was not identified as an independent prognostic factor in our study. Several other studies have reported that involvement of the gallbladder is predictive of poor overall survival [3, 31–33]. In the current study, while involvement of the gallbladder was identified as a poor prognostic factor on univariate analysis, it was not extracted as an independent prognostic factor by multivariate analysis ($p = 0.10$). The reason for this discrepancy is unclear,

but we investigated as many as 18 variables that may potentially affect the prognosis and identified 4 as independent prognostic factors. Recently, several phase III trials have been conducted, besides the ABC-02 study. More effective chemotherapeutic regimens based on gemcitabine are expected to be developed in the near future. The results of this study may help to optimize the design of future clinical trials using gemcitabine.

In conclusion, gemcitabine monotherapy for advanced BTC exhibited modest efficacy with manageable toxicity. PS and serum levels of CRP, CEA and albumin were iden-

tified as independent prognostic factors. These results could be useful in predicting life expectancy, selecting the appropriate treatment strategy and designing future clinical trials for patients with advanced BTC.

Acknowledgments

The authors thank Ms. Kayo Takei and Ms. Keiko Kondo for their devoted work and support.

References

- National Cancer Center. Cancer statistics in Japan 2007. <http://www.fpcr.or.jp/publication/statistics.html> (accessed December 26, 2009).
- Hezel AF, Zhu AX: Systemic therapy for biliary tract cancers. *Oncologist* 2008;13:415-423.
- Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T: A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. *Jpn J Clin Oncol* 2007;37:843-851.
- Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. *Br J Cancer* 2007;96:896-902.
- Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthony A, Iveson T, Highley M, Osborne R, Bridgewater J: Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. *Br J Cancer* 2009;101:621-627.
- Valle JW, Wasan H, Palmer DD, Cunningham D, Anthony A, Maraveyas A, Hughes SK, Roughton M, Bridgewater J: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). *ASCO Annu Meet Proc* 2009;27:abstr 4503.
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92:205-216.
- Todoroki T, Takahashi H, Koike N, Kawamoto T, Kondo T, Yoshida S, Kashiwagi H, Otsuka M, Fukao K, Saida Y: Outcomes of aggressive treatment of stage IV gallbladder cancer and predictors of survival. *Hepatogastroenterology* 1999;46:2114-2121.
- Backes BG, Hauptmann S, Bocking A: Carcinoma of the extrahepatic biliary system: correlation of clinical, pathological, histological and DNA-cytometric parameters with prognosis. *Anticancer Res* 2000;20:1163-1168.
- Saisho T, Okusaka T, Ueno H, Morizane C, Okada S: Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. *Hepatogastroenterology* 2005;52:1654-1658.
- Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH: Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. *Cancer* 2009;115:4148-4155.
- Raderer M, Hejna MH, Valencak JB, Kornek GV, Weindländer GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W: Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. *Oncology* 1999;56:177-180.
- Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebigler W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. *Ann Oncol* 2001;12:183-186.
- Gallardo JO, Rubio B, Fodor M, Orlandi L, Yáñez M, Gamargo C, Ahumada M: A phase II study of gemcitabine in gallbladder carcinoma. *Ann Oncol* 2001;12:1403-1406.
- Lin MH, Chen JS, Chen HH, Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and perihampullary carcinomas. *Chemotherapy* 2003;49:154-158.
- Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaritis H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. *Invest New Drugs* 2004;22:193-198.
- Eng C, Ramanathan RK, Wong MK, Remick SC, Dai L, Wade-Oliver KT, Mani S, Kindler HL: A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. *Am J Clin Oncol* 2004;27:565-569.
- Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, Kim YH: Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. *Jpn J Clin Oncol* 2005;35:68-73.
- von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, Eckel F: Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. *BMC Cancer* 2005;5:61.
- Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. *Cancer Chemother Pharmacol* 2006;57:647-653.
- Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P: The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. *Br J Cancer* 2004;91:205-207.
- McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. *Nutr Cancer* 2001;41:64-69.
- Barreto-Andrade JC, Medina-Franco H: Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas. *Rev Invest Clin* 2009;61:198-204.

- 24 Kushner I: The phenomenon of the acute phase response. *Ann NY Acad Sci* 1982;389:39-48.
- 25 Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC: Induction of rat acute-phase proteins by interleukin 6 in vivo. *Eur J Immunol* 1988;18:717-721.
- 26 Strassmann G, Fong M, Kenney JS, Jacob CO: Evidence for the involvement of interleukin 6 in experimental cancer cachexia. *J Clin Invest* 1992;89:1681-1684.
- 27 Catalano V, Graziano F, Santini D, D'Emidio S, Baldelli AM, Rossi D, Vincenzi B, Giordani P, Alessandrini P, Testa E, Tonini G, Catalano G: Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? *Br J Cancer* 2008;99:1402-1407.
- 28 Watanabe K, Nagai K, Kobayashi A, Sugito M, Saito N: Factors influencing survival after complete resection of pulmonary metastases from colorectal cancer. *Br J Surg* 2009;96:1058-1065.
- 29 Huang O, Chen C, Wu J, Chen S, Chen X, Liu G, Hu Z, Lu J, Wu J, Shao Z, Shen Z, Shen K: Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months. *BMC Cancer* 2009;9:375.
- 30 Okamoto T, Nakamura T, Ikeda J, Maruyama R, Shoji F, Miyake T, Wataya H, Ichinose Y: Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. *Eur J Cancer* 2005;41:1286-1290.
- 31 Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. *J Clin Oncol* 2005;23:2332-2338.
- 32 Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. *Ann Oncol* 2004;15:1339-1343.
- 33 Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T: A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. *Cancer Chemother Pharmacol* 2009;65:113-120.

Long-Term Administration of Wilms Tumor-1 Peptide Vaccine in Combination with Gemcitabine Causes Severe Local Skin Inflammation at Injection Sites

Atsuko Soeda^{1,3}, Yuriko Morita-Hoshi¹, Miho Kaida¹, Takako Wakeda¹, Yuni Yamaki¹, Yasushi Kojima², Hideki Ueno², Shunsuke Kondo², Chigusa Morizane², Masafumi Ikeda², Takuji Okusaka² and Yuji Heike^{1,*}

¹Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, ²Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan and ³Department of Gastroenterology, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Japan

*For reprints and all correspondence: Yuji Heike, Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan. E-mail: yheike@ncc.go.jp

Received March 10, 2010; accepted June 6, 2010

The skin toxicity of vaccine therapy at injection sites is generally limited to Grades 1–2 due to the nature of their function. We experienced two cases of severe and prolonged local adverse effects in 25 patients following a Phase I study of gemcitabine and Wilms tumor-1 peptide vaccine mixed with incomplete Freund's adjuvant for inoperable pancreatic or biliary tract cancer. These patients requested to continue the treatment after the study period; however, in the course of compassionate use, they developed unacceptable local skin reactions and terminated their vaccine treatment. One patient (human leukocyte antigen, A0201, 3 mg) developed Grade 3 ulceration at the 10th vaccination and another (human leukocyte antigen, A2402, 1 mg) developed Grade 2 induration and fibrosis at the 16th vaccination. Skin toxicity occurred at 6.4–8.4 months and continued for several months after the final vaccination during gemcitabine treatment. In these cases, activation or induction of Wilms tumor-1-specific T lymphocytes was not apparent in the peripheral blood despite their severe local reactions. Therefore, we need to monitor patients for late-onset, severe and long-lasting skin reactions at injection sites in Wilms tumor-1 cancer vaccine therapy, particularly for combination treatment with gemcitabine.

Key words: gemcitabine – WT-1 peptide vaccine – incomplete Freund's adjuvant – inflammation – ulcer

INTRODUCTION

The recent development of cancer vaccines has provided insight into anticancer immunity and assisted in the identification of numerous tumor-associated antigens; thus, numerous clinical trials are underway. Therapeutic cancer vaccines are believed to rarely have severe adverse effects. The adverse effects of immunization include systemic reactions and local reactions, such as pain, swelling and erythema. However, these effects are thought to be related to the nature of vaccine function and severe inflammation is very rare. Nevertheless, we experienced two cases showing late-onset and prolonged local inflammation during compassionate use following a Phase I study of gemcitabine (GEM) combined with Wilms tumor-1 (WT-1) peptide vaccine for patients

with advanced pancreatic or biliary duct cancer. They stopped the vaccine and subsequently received only GEM; however, skin inflammation continued even during GEM treatment. In this report, we also examined the relationship between local inflammation and immunological status in the peripheral blood of these patients.

CASE REPORTS

CASE 1

A 73-year-old woman was diagnosed as having intrahepatic cholangiocellular carcinoma (mass-forming type, moderately differentiated adenocarcinoma, T2N1M0, stage

IIIC) and a tumor mass of 48 × 45 × 45 mm in the left lobe of her liver was resected in May 2007. In March 2008, small lung metastatic lesions and pelvic bone metastasis were detected using CT examination. After palliative radiation therapy for bone metastasis, she consented to enter a Phase I study of the combined GEM and WT-1 peptide vaccine. The schedule and vaccine injection sites are shown in Fig. 1A and B. She had human leukocyte antigen (HLA)-A0201 genotype and received 3-mg HLA-A0201 restricted WT-1 peptide vaccine (aa126–134 RMFPNAPYL mixed with Montanide ISA 51 VG). She had Grade 1 hematological toxicity, fatigue, anorexia, nausea and vomiting caused by GEM. Local adverse effects of the vaccine (Grades 1–2: erythema, itching and nodules) appeared after the second vaccination. The maximum redness diameter was 40 mm forming a nodule after the fourth vaccination during the study period. Local inflammation was stable up to the eighth vaccination. However, redness exacerbated after the ninth vaccination to 30–40 mm, and ulcers developed at the vaccination sites on both arms after the 10th vaccination. Vaccine was discontinued as a result of ulcer development (Grade 3) (Fig. 2), although GEM was continued because disease status was stable. Despite vaccination discontinuation, she developed ulceration at the abdominal and femoral sites during continuous GEM treatment. After 2 further months, she developed obstructive jaundice. A biliary stent was inserted and GEM treatment was stopped for 1 month. Nonetheless, ulceration remained in the femoral areas, and although other sites of ulceration were covered with granulation, redness and effusion remained. The maximal response was stable disease according to RECIST criteria, although the size of small lung metastases decreased, CEA decreased from 10.7 to 3.0 ng/ml (normal, <5 ng/ml), and CA19-9 decreased from 425 to 108 U/ml (normal, <37 U/ml).

CASE 2

A 73-year-old woman was diagnosed with gall bladder carcinoma [nodular type, well-differentiated tubular adenocarcinoma, T3N0M1 (peritoneum), stage IV] in January 2008. The tumor mass was 30 mm with direct invasion of the liver. She consented to enter this study. She had HLA-A2402 genotype, and received 1-mg modified HLA-A2402-restricted WT-1 peptide vaccine (modified 9-mer peptide aa235–243 CYTWNQMNL mixed with Montanide ISA 51 VG). Her treatment schedule was the same as in Case 1 (Fig. 1A and B). She had Grade 1 hypoalbuminemia, fatigue, anorexia, nausea and Grade 2 anemia caused by GEM. Local adverse effects of the vaccine (red, itching and nodule) appeared after the first injection and the maximum redness diameter was 20 mm with a nodule after the fourth vaccination. The inflammation sizes were almost no change however she complained of itching at the injection sites after the eighth vaccination and non-steroidal anti-inflammatory ointment was administered. After the 16th vaccination, she was unable to continue immunization due to strong itching and felt limitation of motility in her arms and thighs at the injection sites because of tightened skin. GEM treatment was continued because the disease status remained stable. Local reactions (redness and nodules) and itching remained for 3 months after the final vaccination (Fig. 2). The maximal response was stable disease.

IMMUNOLOGICAL STATUS IN THE PERIPHERAL BLOOD

We frequently monitored immunological status with peripheral blood samples (Fig. 1A) from the patients according to the study protocol. We performed surface maker staining, WT1 multimer staining (HLA-A0201 WT-1 Dextramer [RMFPNAPYL], HLA-2402 WT-1 Dextramer [CMTWNQMNL], modified WT-1 Dextramer




Figure 1. Study schedule and sites of immunization injection. Gemcitabine (GEM) was injected once weekly for 3 weeks with a 1-week rest period (black arrows) and WT-1 peptide vaccine was initiated on day 8 and injected biweekly (gray arrow). Treatment continued until disease progression (A). Peptide vaccine was injected intradermally at each of the six sites (100 µl) (B).




Figure 2. Injection sites in Cases 1 and 2. White arrows indicate ulcers. Inflammation continued for months even after immunization was terminated due to local adverse effects.

[CYTWNQMNL] were obtained from Immudex [Copenhagen, Denmark]. HLA-A0201 WT-1 Pentamer [RMFPNAPYL] was purchased from Proimmune [Oxford, UK], intracellular cytokine staining by WT1 peptide stimulation and WT1-specific tetramer staining (HLA-A0201 WT-1 Tetramer [RMFPNAPYL], HLA-2402 modified WT-1 Tetramer [CYTWNQMNL]) after mixed lymphocyte and peptide culture (MLPC). The methods are shown in our previous study (1–2). In the surface marker staining, the absolute number of CD69⁺ CD8⁺ T cells, CD14⁺ monocytes, and CD11c⁺ and CD123⁺ dendritic cells increased throughout the trial (Fig. 3A). We did not detect consistent evidence of WT1-specific lymphocyte induction in either case by multimer staining and intracellular cytokine staining; however, after MLPC a small number of WT1 tetramer binding cells were detected in Case 1 (Fig. 3B).

DISCUSSION

Clinical trials of cancer vaccines, particularly peptide vaccines, are typically carried out with no significant toxicities, although Grade 1–2 local inflammation is common. While most participants experience discomfort at local injection sites, these effects are not regarded as serious. However, some studies published over the past 10 years have reported Grade 3 local adverse effects (3–8). All of these trials targeted melanoma patients, and although the peptides were different in each study, they were all emulsified with incomplete Freund’s adjuvant (IFA). Some studies added cytokines, such as interleukin-12, granulocyte-macrophage colony-stimulating factor, interferon- α 2b and interleukin-2 (3,5–6, 8). The volume of IFA was over 1 ml and doses were administered subcutaneously (3–4,8) or injected both intradermally and subcutaneously (5–7). The schedules for

vaccination ranged from weekly to monthly intervals, and the total number of immunizations was 6–26 in limbs or at primary sites. The frequency of Grade 3 events at local injection sites ranged from 2.6 to 24%, and included ‘local pain’ (3), ‘ulceration’ (4) or ‘injection site reactions’ (5–8).

In our study, we used intradermal injections of 600 μ l of peptide/IFA emulsion at six injection sites (100 μ l at each site), as this delivers the antigen directly to dermal dendritic cells. Recent studies on the influenza vaccine have compared intradermal and intramuscular routes, and have confirmed the superiority of intradermal vaccination for immunological response; however, this also leads to an increase in local adverse effects (9–12). Some studies on prophylactic vaccines have also reported comparisons between percutaneous and intradermal immunization (13–15). Most of these have concluded that the response to intradermal immunization is better than that to subcutaneous immunization, although one study showed an increase in local inflammation after intradermal injection (15). Intradermal immunization may cause stronger local inflammation than other methods of vaccination.

We also used GEM in this study. Our preliminary study on the immunological effects of GEM treatment showed an increase in dendritic cells and monocytes (1). The increase in dendritic cells may have had an effect on local inflammation at the injection sites in the present chemoimmunotherapy regimen. We could not elucidate the mechanisms of severe local reactions in this trial, and planning a skin biopsy and immunohistochemical examination in future trials.

We frequently monitored immunological status with peripheral blood samples. However, we did not detect consistent evidence of antigen-specific lymphocyte induction by immunization in circulating blood without cell expansion. Furthermore, we did not detect any evidence of




Figure 3. Kinetics of immune cells and mixed lymphocyte and peptide culture (MLPC). CD69⁺ CD8⁺ T cells, CD14⁺ monocytes, CD123⁺ and CD11c⁺ dendritic cells increased in both patients (A). Induction of WT-1-specific CTL was detected in Case 1 by MLPC; however, the percentage was very low (B).

WT-1-specific lymphocytes after vaccination in Case 2, despite severe local inflammation. There may be several immunological discrepancies between local inflammation and peripheral blood samples. Thus, injection site reactions may not always induce comparable objective immunological reactions. We are preparing a report including the immunomonitoring data in our trial in another manuscript. It is also difficult to manage local adverse effects, as there are no standardized terms in common terminology criteria for adverse events to express local injection site reactions in cancer vaccine trials. We experienced conflicts with regard to the terms and definitions for the grades to apply to local reactions. Agreement is therefore needed in order to accurately characterize local reactions before vaccine trials.

Although vaccine therapies are believed to have essentially no severe adverse effects and are considered to be a safe therapeutic strategy, we observed rather serious local injection site reactions, even after treatment was discontinued. Thus, patients must be adequately informed about these unpleasant local reactions, and close observation should be extended until the later phase of study.

Acknowledgements

We are indebted to Ms. Makiko Shimada, Ms. Rui Kuroda and Ms. Noriko Takahashi, whose technical advice made enormous contributions to our work. We would also like to thank Immudex and Dako Japan for providing the Dextramers and IBL for providing Tetramers used in this study.

Funding

This study was supported by Grants-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan and grants from the Advanced Clinical Research Organization (ACRO).

Conflict of interest statement

None declared.

References

1. Soeda A, Morita-Hoshi Y, Makiyama H, Morizane C, Ueno H, Ikeda M, et al. Regular dose of gemcitabine induces an increase in CD14⁺ monocytes and CD11c⁺ dendritic cells in patients with advanced pancreatic cancer. *Jpn J Clin Oncol* 2009;39:797–806.
2. Morita Y, Hosokawa M, Ebisawa M, Sugita T, Miura O, Takaue Y, et al. Evaluation of cytomegalovirus-specific cytotoxic T-lymphocytes in patients with the HLA-A*02 or HLA-A*24 phenotype undergoing hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2005;36:803–11.
3. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. *J Clin Oncol* 2001;19:3836–47.
4. Smith JW, II, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8⁺ T-cell responses. *J Clin Oncol* 2003;21:1562–73.
5. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of vaccination with a multipeptide melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. *J Clin Oncol* 2004;22:4474–85.

6. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. *Clin Cancer Res* 2007;13:6386–95.
7. Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. *J Clin Oncol* 2008;26:4973–80.
8. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, Sander C, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine +/- granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. *Clin Cancer Res* 2009;15:1443–51.
9. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. *N Engl J Med* 2004;351:2286–94.
10. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. *N Engl J Med* 2004;351:2295–301.
11. Chiu SS, Peiris JS, Chan KH, Wong WH, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. *Pediatrics* 2007;119:1076–82.
12. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. *J Infect Dis* 2008;198:650–8.
13. Halperin W, Weiss WI, Altman R, Diamond MA, Black KJ, Iaci AW, et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. *Am J Public Health* 1979;69:1247–51.
14. Warrell MJ, Suntharasamai P, Nicholson KG, Warrell DA, Chanthavanich P, Viravan C, et al. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. *Lancet* 1984;1:874–6.
15. Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guerin. *J Infect Dis* 1996;174:113–9.

Original Article

A Phase I/II Study of Combined Chemotherapy with Mitoxantrone and Uracil/Tegafur for Advanced Hepatocellular Carcinoma

Eiichiro Suzuki^{1,2*}, Junji Furuse², Masafumi Ikeda¹, Hiroshi Ishii³, Takuji Okusaka⁴, Kohei Nakachi¹, Shuichi Mitsunaga¹, Hideki Ueno⁴ and Chigusa Morizane⁴

¹Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Chiba, ²Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, ³Hepatobiliary and Pancreatic Section, Gastroenterological Division, Cancer Institute Hospital and ⁴Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan

*For reprints and all correspondence: Eiichiro Suzuki, Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo 181-8611, Japan. E-mail: eisuzuki@ks.kyorin-u.ac.jp

Received July 5, 2010; accepted October 28, 2010

Objective: The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part).

Methods: Patients eligible had histologically confirmed, chemo-naïve advanced hepatocellular carcinoma and were amenable to established forms of treatment. The therapy consisted of mitoxantrone administered intravenously at one of three dosages (6, 8 and 10 mg/m²/day) on day 1 and uracil/tegafur administered orally at 300 mg/m² from day 1 through day 21. The treatment was repeated every 4 weeks until evidence of tumor progression or unacceptable toxicity.

Results: A total of 25 patients were enrolled. In the Phase I part, dose-limiting toxicities occurred in all three patients, given mitoxantrone at the dosage of 10 mg/m²/day, and the recommended mitoxantrone dosage was determined to be 8 mg/m²/day. Among 19 patients administered the drug at the recommended dosage, 1 patient (5.3%) showed partial response, 8 patients (42.1%) showed stable disease and 10 patients (52.6%) showed progressive disease. The median survival and median progression-free survival were 8.4 and 2.5 months, respectively. The most common toxicities were Grade 3–4 leukopenia (63.2%) and neutropenia (68.4%).

Conclusions: Mitoxantrone at 8 mg/m² combined with uracil/tegafur at 300 mg/m²/day was determined to be the recommended regimen. Although this regimen was generally well tolerated, it appeared to have little activity against advanced hepatocellular carcinoma. These findings do not support the use of this combination regimen in practice.

Key words: hepatocellular carcinoma – chemotherapy Phase I/II – mitoxantrone – uracil/tegafur

INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most commonly occurring cancers worldwide (1,2). Surgical resection, liver transplantation and local ablation therapy, including radiofrequency ablation and ethanol injection, are considered as curative treatment for HCC (3). Transcatheter arterial

chemoembolization (TACE) has been applied to patients with advanced incurable HCC (4,5). However, the majority of HCC patients develop recurrence or metastasis, regardless of the treatment modalities employed. Although patients with HCC at this advanced stage are generally treated by systemic therapy, the prognosis remains poor (6,7). Sorafenib

is an orally administered molecular-targeted drug that targets tumor cell proliferation and tumor angiogenesis by inhibiting the serine–threonine kinases Raf-1 and B-Raf and the receptor tyrosine kinase activity of vascular endothelial growth factor receptors 1, 2 and 3 and platelet-derived growth factor receptor β . This drug was reported to confer an overall survival advantage, with manageable toxicity, in comparison with placebo in a Phase III trial, and it has been accepted worldwide as the first-line chemotherapy for advanced HCC (8). But the advantage is modest. There is urgent need to develop more effective regimens.

5-Fluorouracil (5-FU) has been widely used for the treatment of various gastrointestinal malignancies, including advanced HCC (9,10). A high level of efficacy can be expected when the drug is given as a continuous intravenous infusion (11). However, this would necessitate a permanent intravenous access. Uracil/tegafur (UFT) is an orally administered drug which is a mixture of uracil and tegafur at a molar ratio of 4:1. Tegafur is a prodrug of 5-FU that is hydroxylated and converted to 5-FU by hepatic microsomal enzymes, and uracil prevents the degradation of 5-FU by inhibiting the enzyme dihydropyrimidine dehydrogenase, which results in an increased level of 5-FU in the plasma and tumor tissues (12,13). UFT has been reported to be as effective as intravenous 5-FU for the treatment of malignancies (14,15) and to be effective for the treatment of advanced HCC (16,17).

The therapeutic usefulness of doxorubicin in patients with advanced HCC has also been widely explored since the 1970s. A randomized trial in which doxorubicin was compared with supportive care alone for advanced HCC showed a significant survival benefit in the doxorubicin arm. However, treatment with this drug has not been accepted as a standard chemotherapy because of the high rate of fatal complications reported (18). Mitoxantrone, another anthracycline, has shown similar antitumor activity to that of doxorubicin in both human tumor cell lines and animal models of leukemia and has fewer myelotoxic and cardiotoxic effects than doxorubicin (19). Clinical trials of mitoxantrone have also demonstrated moderate activity against HCC, with a low incidence rate of adverse effects (20,21).

Combination chemotherapeutic regimens composed of a fluoropyrimidine and an anthracycline antibiotic have been reported to show moderate efficacy against HCC with tolerable toxicity (22–24), but combined chemotherapy with UFT and mitoxantrone has not yet been examined. We conducted Phase I/II studies to determine the recommended dosage of the combination of UFT with mitoxantrone (UFM regimen) and to clarify the efficacy and safety when administered at the recommended dose in patients with advanced HCC.

PATIENTS AND METHODS

ELIGIBILITY CRITERIA

The eligibility criteria for study enrolment were: (i) patients with histologically confirmed HCC, who were (ii) unsuitable

for surgical resection, local ablation therapy or TACE, (iii) were ≥ 20 years old, (iv) had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2, (v) had adequate bone marrow function (white blood cell ≥ 3000 cells/mm³, absolute neutrophil count ≥ 1500 cells/mm³, platelet count $\geq 70\,000$ cells/mm³ and hemoglobin ≥ 8.0 g/dl), renal function [serum creatinine concentration \leq upper limit of normal (ULN)] and hepatic function [serum albumin level ≥ 3.0 mg/dl, total bilirubin level ≤ 3.0 mg/dl, serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels $\leq 5.0 \times$ ULN], (vi) had a life expectancy of at least 12 weeks and (vii) provided written informed consent from each patient.

The exclusion criteria were: clinically evident congestive heart failure, serious cardiac arrhythmia, active or symptomatic coronary artery disease or ischemia, clinically serious infection, seizure disorder requiring medication, prior malignancy (any cancer treated curatively was permitted), clinically evident brain or meningeal metastasis, and pregnant/lactating women. This protocol was approved by the Institutional Review Board for clinical investigation of the National Cancer Center, in conformity with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations.

STUDY TREATMENT

UFT was administered orally at the dose of 300 mg/m² per day in two divided doses for 21 consecutive days, followed by a rest period of 7 days (400 mg/body per day in patients with a body surface area of < 1.50 m² and 500 mg/body/day in patients with a body surface area of ≥ 1.50 m²). Mitoxantrone was given as a 60 min intravenous infusion on day 1. This cycle was repeated every 28 days. Patients continued to receive additional courses of this regimen until a cumulative dose of mitoxantrone of 100 mg/m², evidence of disease progression or the appearance of unacceptable toxicity.

PHASE I PART

The objectives of the Phase I study were to investigate the frequency of dose-limiting toxicity (DLT) and to determine the recommended dose of mitoxantrone and UFT. The criteria of DLT included: Grade 4 leukopenia or neutropenia, Grade 3 neutropenia accompanied by fever ($\geq 38^\circ\text{C}$) or infection (clinically or biologically confirmed), thrombocytopenia $< 25\,000/\text{mm}^3$ or necessity of transfusion, Grade 3 or 4 non-hematological toxicity (except nausea/vomiting, anorexia, fatigue and hyperglycemia), AST and ALT > 10 times the ULN, suspension of UFT administration for over 3 successive weeks, or an over 6-week delay in the commencement of the next treatment cycle.

Three possible dosage levels of mitoxantrone (Level 1: 6 mg/m²/day, Level 2: 8 mg/m²/day and Level 3: 10 mg/m²/day) were assigned for the Phase I part (Table 1). The first

Table 1. Dose-escalation schedules of mitoxantrone and uracil/tegafur

Dose level	Mitoxantrone (mg/m ²)	UFT (mg/m ²)	Number of patients enrolled
1	6	300	3
2	8	300	6
3	10	300	3

UFT, uracil/tegafur.

patient to enter the study was started at Level 1. At least three patients were treated at this level and observed for DLT. Dose escalation was continued until at least one-third of the patients in a given cohort showed DLT. If none of the first three treated patients developed DLT during the first cycle at a specific dose level, the dose escalation was continued. If one of the first three treated patients developed DLT at any dose level, three additional patients were entered at the same dose level; if only one or two of six patients at a given level experienced a DLT, the dose escalation was continued. The maximum tolerated dose (MTD) was defined as the dose level at which one-third or more of the patients experienced a DLT. The recommended dose for the Phase II study was defined as the dose level preceding the attainment of the MTD.

PHASE II PART

The primary endpoint of the Phase II part was the objective response rate. The secondary endpoints were the overall survival, progression-free survival and the frequency and severity of adverse events. The Phase II part was begun after determination of the recommended dosage from the Phase I part.

ASSESSMENT OF THE RESPONSE AND TOXICITY

Physical examination including cardiac symptoms, complete blood cell counts, serum chemistries and urinalysis was performed at the baseline and at least once every 2 weeks after the start of the treatment. Dynamic computed tomography or magnetic resonance imaging was undertaken to evaluate the response at 4- to 6-week intervals after the start of treatment. Tumor response was assessed using the Response Evaluation Criteria in Solid Tumors (25). Toxicity was graded according to the National Cancer Institute common toxicity criteria, version 2.0. Progression-free survival was calculated from the first day of treatment to the appearance of evidence of tumor progression, clinical progression or last date of follow-up. The overall survival was calculated from the first day of treatment until death due to any cause or date of last follow-up. Survival data were analyzed using the Kaplan–Meier method.

STATISTICAL ANALYSIS

In the Phase II part, the primary endpoint was the response rate, and data from at least 19 patients were accrued. The threshold response rate was set at 5% and the expected response rate at 15%. If no responses were observed in the 19 patients and the upper limit of the 90% confidence interval (CI) did not exceed the expected rate of 15%, the UFM regimen was judged to have no activity against HCC. If response was confirmed in one or more of the 19 patients, the decision of whether or not to proceed to a further study using the UFM regimen was taken on the basis of other factors, such as the safety and rate of response, overall survival and time to progression in this study.

RESULTS

PATIENTS

From April 2004 to April 2007, 25 patients were registered for the present study: 12 patients completed the Phase I part (Level 1: 3 patients, Level 2: 6 patients and Level 3: 3 patients). Nineteen patients who received the recommended dose (6 patients received this dose during the Phase I part) were analyzed during the Phase II part. Table 2 shows the baseline characteristics of the patients in the Phase I and Phase II parts of the study of the UFM regimen. There were 19 males and 6 females with a median age of 67 years. All the patients had a good ECOG PS score of 0–1. There were 21 (84%) and 4 (16%) patients with the Child–Pugh Stages A and B, respectively. Thirteen (68%) patients had extrahepatic metastasis, and the major sites of metastasis were lymph node [*n* = 7 (28%)] and lung [*n* = 6 (24%)].

TREATMENTS

In the Phase I part, there was no occurrence of DLT at the Level 1 and Level 2 doses, but all of the three patients who received the Level 3 dose experienced DLT; two of these patients developed Grade 4 neutropenia and one patient developed Grade 3 creatinine elevation. The additional three patients at the Level 2 dose did not experience any DLT. Therefore, Level 3 was considered as the MTD and Level 2 (UFT 300 mg/m² and mitoxantrone 8 mg/m²) as the recommended dose for the Phase II part.

At the recommended dosage level, a total of 69 courses of the UFM regimen were administered with a median of three courses to each patient (range, 1–8 courses). The dose intensity was 98.9% of the planned dosage for mitoxantrone and 97.9% for UFT.

The reasons for treatment discontinuation in the Phase I and Phase II parts were disease progression in 19 patients, liver dysfunction in 1 patient, DLT according to this protocol in 3 patients during the Phase I part and an over 6-week delay in the start of the next course because of the development of leukopenia in 2 patients. After abandoning the UFM

Table 2. Profile of hepatocellular carcinoma patients population

	Phase I	Phase II
No. of patients	12	19
Gender		
Male	9	14
Female	3	5
Age (years)		
Median	63	67
Range	56–78	56–77
Performance status		
0	11	7
1	1	12
Viral marker		
Hepatitis C antibody+	7	7
Hepatitis B antigen+	2	5
Previous treatment		
Surgical resection	4	10
Percutaneous ablation therapy	3	3
Transcatheter arterial chemoembolization	5	8
Transcatheter arterial infusion	3	5
Radiation therapy	1	2
None	3	3
Child–Pugh classification		
A	8	17
B	4	2
UICC tumor stage ^a		
III	4	6
IVa	3	1
IVb	5	12
Portal vein tumor thrombosis		
(+)	5	4
Extrahepatic metastasis		
Lymph node	5	7
Lung	0	6
Bone	0	3
Adrenal gland	0	1
Peritoneum	0	1
None	7	6

^aThe International Union Against Cancer, 6th edition.

regimen, 10 patients received the second-line treatment. Five patients received systemic chemotherapy, one patient received UFT alone and four patients received a combined chemotherapy with UFT and doxorubicin. Two patients received transcatheter arterial infusion with cisplatin, one patient received salvage TACE because of HCC rupture during the follow-up period, one patient received salvage

Table 3. Toxicity

Toxicity grade	Phase I part									Phase II part		
	Level 1 (n = 3)			Level 2 (n = 6)			Level 3 (n = 3)			Level 2 (n = 19)		
	1–2	3	4	1–2	3	4	1–2	3	4	1–2	3	4
Hematological toxicity												
Leukopenia	2	1	0	0	2	0	0	1	1	4	9	3
Neutropenia	0	1	0	0	2	0	0	0	2	4	11	2
Thrombocytopenia	1	1	0	0	0	0	1	0	0	4	1	0
Anemia	0	0	0	1	0	0	0	0	0	1	0	0
Non-hematological toxicity												
Nausea	3	0	0	0	0	0	2	0	0	3	0	0
Anorexia	0	0	0	2	0	0	1	0	0	3	0	0
Elevated bilirubin	2	0	0	0	1	0	1	0	0	6	0	0
Hypoalbuminemia	1	0	0	0	0	0	0	0	0	1	0	0
Fatigue	0	0	0	0	0	0	1	0	0	1	0	0
Hyperpigmentation	0	0	0	0	0	0	0	0	0	1	0	0
Constipation	0	0	0	0	0	0	0	0	0	1	0	0
Elevated creatinine	0	0	0	0	0	0	0	1	0	0	0	0
Elevated AST	0	0	0	1	0	0	0	0	0	2	1	1 ^a
Elevated ALT	0	0	0	1	0	0	0	0	0	1	2	1 ^a
Liver dysfunction	0	0	0	0	0	0	0	0	0	0	0	1 ^a

AST, aspartate aminotransferase; ALT, alanine aminotransferase.

^aDeath related to adverse event.

radiofrequency ablation because of rapid growth of HCC that needed control and one patient received immunotherapy.

TOXICITY

Table 3 summarizes the toxicities observed in the patients. At the recommended dose (level 2), the major Grade 3–4 hematological toxicities were leukopenia (63.2%) and neutropenia (68.4%). The most common non-hematological toxicities were elevated serum total bilirubin level (31.6%), elevated AST level (26.3%), elevated ALP level (26.3%) and anorexia (21.1%); however, no Grade 3–4 non-hematological toxicities were observed. One patient died of hepatic failure due to hepatitis B virus (HBV) reactivation.

EFFICACY

Of the 19 patients who were administered the recommended dosage, 18 died during the follow-up period. All of the 19 patients administered the recommended dosage were evaluable for tumor response; of these, 1 patient achieved partial response (PR), with an overall response rate of 5.3% (95% CI, 0.0–26.0%). Eight patients (42.1%) had stable disease